Hot Topic: Women’s health – hurdles and hope

Developing medicines for health problems that exclusively or disproportionately affect women has never been easy.

There seem to be a whole line of extra hurdles to clear, from the social to the scientific.

But this year there does seem to be more hope.

Some of the world’s biggest pharma firms, such as Eli Lilly, UCB and Novo are expressing real interest in the area.

And most major life science investing events now have at least one panel on the subject, with BIO-Europe and London Life Science Week this month hosting interesting discussions.

These discussions are still very much focused on the hurdles – asking “How can we do this?”, rather than “Look what we’ve done”.

But the fact these questions are now getting a good airing, is hopeful in itself.

So what are the hurdles?

On a panel at the LSX Investival in London last Monday, everyone agreed on the need for more data, and a better understanding of fundamental biology.

Anastasiya Sybrina, of Jeito, a VC, said the more positive data there is in a women’s health condition, such as endometriosis, the more appetite there will be from investors.

Solid data depends on trials which aren’t always straightforward – and have to be funded. In endometriosis, for instance, surgery is needed for gold-standard diagnosis, limiting the pool of potential participants.

In other conditions which affect women during pregnancy, or even while trying to conceive, there is understandable reluctance to be involved in clinical trials of an experimental medicine – and rules governing such trials can be incredibly tight too. More than 50 years later, the thalidomide scandal still looms large.

Reliable biomarkers which can be used not just to diagnose common women’s health conditions – but also assess how they change in response to treatment – are also needed.

Here there’s been some movement, with the FDA accepting bone density surrogates for osteoporosis, said Melissa Simon of Wieland Capital, a family investment office. That’s way better than the old system of waiting for bones to break.

Oliver Lyth of M Ventures, a corporate VC, said: “Regulators hold a lot of power and need to be bold and innovative. If they are willing to accept a surrogate or secondary endpoint, that’s going to help companies raise money.”

Another hurdle is that fact there simply aren’t many big pharma firms interested in acquiring assets, Lyth added – noting it was “great to see” the likes of Eli Lilly and Novo were getting interested.

Agnes Arbat, CEO of Oriva, which is developing novel treatments in endometriosis and uterine fibroids, said because of this, women’s health biotechs needed to persevere – and accept that they’d hear a lot of “nos” on the road to “yeses”.

So why is the buying pool so small? The fact men have tended to lead major pharma firms has something to do with it – historically at least.

And as Melissa Simon pointed out, there’s also been a tendency to underestimate the willingness and ability of women to pay for treatment that’ll help them live fulfilling and pain-free lives.

It’s interesting to see that Eli Lilly and Novo appear to be leading the charge here. Of course, they’ve got more cash than most so they can take a few more chances.

But maybe it’s also because they realise that women are actually willing to pay for a drug that improves their lives. After all, as I previously discussed on Hot Topic, four in five people paying privately for GLP-1s are women.

If that isn’t proof that the market for chronic health conditions that affects women is huge, I don’t know what is.

© Optimum Strategic Communications.